SOURCE: The Bedford Report

The Bedford Report

August 26, 2011 08:16 ET

Encouraging Pipelines From Pluristem and Fibrocell Science Gain Attention

The Bedford Report Provides Equity Research on Pluristem Therapeutics & Fibrocell Science

NEW YORK, NY--(Marketwire - Aug 26, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation, and discoveries continue to elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Plursitem Therapeutics, Inc. (NASDAQ: PSTI) and Fibrocell Science, Inc. (OTCBB: FCSC). Access to the full company reports can be found at:

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies.

According to Thomson Reuters, on average biotech companies in the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D in 2010, reflecting a 7 percent decline from 2009.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Fibrocell Science is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Earlier this summer regulators approved the company's cell-based dermal filler, Laviv.

Shares of Pluristem Therapeutics surged earlier this week after the FDA designated Pluristem's PLX cells orphan status for the treatment of thromboangiitis obliterans. The Company also announced that a concurrent application in Europe at the EMA's Committee for Orphan Medicinal Products is pending.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information